Flavio Steinwurz
Overview
Explore the profile of Flavio Steinwurz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Regueiro M, Siegmund B, Yarur A, Steinwurz F, Gecse K, Goetsch M, et al.
J Crohns Colitis
. 2024 May;
18(10):1596-1605.
PMID: 38700040
Background And Aims: Infections are a safety concern in patients with ulcerative colitis [UC]. Etrasimod is an oral, once daily [QD], selective sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment...
2.
Steinwurz F, Machado M, Veitia G, De Paula J, Bautista Martinez S, Vergara B, et al.
Therap Adv Gastroenterol
. 2023 Dec;
16:17562848231207312.
PMID: 38144423
Background: Inflammatory bowel diseases (IBDs) are chronic conditions that negatively interferes with the quality of life of the patients, on a physical, emotional, and social level. Its symptoms can vary...
3.
Hammoudi N, Sachar D, DHaens G, Reinisch W, Kotze P, Vermeire S, et al.
J Crohns Colitis
. 2023 Dec;
18(6):943-957.
PMID: 38112601
Background: Outcomes after ileocolonic resection in Crohn's disease [CD] are heterogeneous, and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization...
4.
Dotti A, Magro D, Vilela E, Chebli J, Chebli L, Steinwurz F, et al.
Crohns Colitis 360
. 2023 Oct;
5(4):otad053.
PMID: 37859629
Background: In real-world experience, the number of patients using vedolizumab as first-line biological therapy was low. We aimed to evaluate the effectiveness and safety of vedolizumab in mild-to-moderate Crohn's disease...
5.
Perin R, Magro D, Andrade A, Argollo M, Carvalho N, Damiao A, et al.
Crohns Colitis 360
. 2023 Feb;
5(1):otac050.
PMID: 36777366
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease which affects the colorectal mucosa with a relapsing-remitting pattern. The therapeutic options currently available for the medical management of UC...
6.
Lee S, Allegretti J, Steinwurz F, Connelly S, Lawendy N, Paulissen J, et al.
BMC Gastroenterol
. 2023 Feb;
23(1):34.
PMID: 36755231
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We evaluated tofacitinib efficacy and safety in the 52-week maintenance study, OCTAVE Sustain, by...
7.
Targownik L, Dubinsky M, Steinwurz F, Bushmakin A, Cappelleri J, Tai E, et al.
J Crohns Colitis
. 2022 Oct;
17(4):513-523.
PMID: 36271912
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis [UC]. We evaluated the relationship between Mayo/Inflammatory Bowel Disease Questionnaire [IBDQ] scores and Work...
8.
Rosseto-Welter E, Dargenio-Garcia L, Lopes F, Zulim Carvalho A, Flaquer F, Severo-Lemos V, et al.
Can J Gastroenterol Hepatol
. 2022 Aug;
2022:1307159.
PMID: 35959163
Crohn's disease (CD) is a chronic inflammatory disease with a complex interface of broad factors. There are two main treatments for Chron's disease: biological therapy and nonbiological therapy. Biological agent...
9.
Vavricka S, Greuter T, Cohen B, Reinisch W, Steinwurz F, Fellmann M, et al.
Therap Adv Gastroenterol
. 2022 May;
15:17562848221090834.
PMID: 35574426
Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Here, we report steroid-free efficacy and safety with tofacitinib among patients with UC...
10.
Ananthakrishnan A, Kaplan G, Bernstein C, Burke K, Lochhead P, Sasson A, et al.
Lancet Gastroenterol Hepatol
. 2022 Apr;
7(7):666-678.
PMID: 35487235
Environmental and lifestyle factors play an important role in the natural history of Crohn's disease and ulcerative colitis. A group of international experts from the International Organization for the Study...